BioSpace News Archive

Fulgent Genetics, Inc. today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Wednesday February 23, 2022.

Therapeutic Solutions International announced today positive preclinical efficacy and safety data using its newly announced CampbellCell™ allogeneic primed mesenchymal stem cell.

Trinity Biotech plc (Nasdaq: TRIB) has received approval for its new HIV screening product, TrinScreen™ HIV, from the World Health Organisation (WHO).

NTT Research, Inc. , a subsidiary of NTT (TYO:9432), today announced that Dr. Elette Boyle has joined the Cryptography & Information Security (CIS) Lab as a senior scientist.

Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, announced the completion of a $5.9 million in gross proceeds capital raise.

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today provided progress updates on its early-stage programs, including the pan-cancer fibroblast activation protein-alpha (FAP-alpha) inhibitor program PNT2004, and the next-generation actinium-225 PSMA targeted program PNT2001.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the publication of the PICTURE study in Orphanet Journal of Rare Disease.

Advanced Oxygen Therapy Inc. announced today a number of significant additions to its Leadership Team, bringing to the company over 100 years of combined strategic experience.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), announces that new research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “statistically significant improvements” in a number of motor function measurements.

ValGenesis, Inc., a market leader in enterprise Validation Lifecycle Management Systems (VLMS), today announced that a French pharmaceutical company selected ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system – to digitize its corporate validation process.